112 related articles for article (PubMed ID: 12573320)
1. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride.
Ben-David I; Rozen Y; Ortu G; Mishani E
Appl Radiat Isot; 2003 Feb; 58(2):209-17. PubMed ID: 12573320
[TBL] [Abstract][Full Text] [Related]
2. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.
Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E
Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961
[TBL] [Abstract][Full Text] [Related]
3. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors.
Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M
Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
7. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
[TBL] [Abstract][Full Text] [Related]
8. Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Gao M; Lola CM; Wang M; Miller KD; Sledge GW; Zheng QH
Bioorg Med Chem Lett; 2011 Jun; 21(11):3222-6. PubMed ID: 21549594
[TBL] [Abstract][Full Text] [Related]
9. A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
Hirata M; Kanai Y; Naka S; Yoshimoto M; Kagawa S; Matsumuro K; Katsuma H; Yamaguchi H; Magata Y; Ohmomo Y
Ann Nucl Med; 2013 Jun; 27(5):431-43. PubMed ID: 23494210
[TBL] [Abstract][Full Text] [Related]
10. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.
Bonasera TA; Ortu G; Rozen Y; Krais R; Freedman NM; Chisin R; Gazit A; Levitzki A; Mishani E
Nucl Med Biol; 2001 May; 28(4):359-74. PubMed ID: 11395308
[TBL] [Abstract][Full Text] [Related]
11. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
VanBrocklin HF; Lim JK; Coffing SL; Hom DL; Negash K; Ono MY; Gilmore JL; Bryant I; Riese DJ
J Med Chem; 2005 Nov; 48(23):7445-56. PubMed ID: 16279804
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.
Fredriksson A; Johnström P; Thorell JO; von Heijne G; Hassan M; Eksborg S; Kogner P; Borgström P; Ingvar M; Stone-Elander S
Life Sci; 1999; 65(2):165-74. PubMed ID: 10416822
[TBL] [Abstract][Full Text] [Related]
13. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
[TBL] [Abstract][Full Text] [Related]
14. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor.
Dissoki S; Aviv Y; Laky D; Abourbeh G; Levitzki A; Mishani E
Appl Radiat Isot; 2007 Oct; 65(10):1140-51. PubMed ID: 17574425
[TBL] [Abstract][Full Text] [Related]
15. 4-aminoquinazoline analogs: a novel class of anticancer agents.
Singh K; Sharma PP; Kumar A; Chaudhary A; Roy RK
Mini Rev Med Chem; 2013 Jun; 13(8):1177-94. PubMed ID: 22697512
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
Wang JQ; Gao M; Miller KD; Sledge GW; Zheng QH
Bioorg Med Chem Lett; 2006 Aug; 16(15):4102-6. PubMed ID: 16697188
[TBL] [Abstract][Full Text] [Related]
17. Small Molecule T315 Promotes Casitas B-Lineage Lymphoma-Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation.
Huang KY; Kao SH; Wang WL; Chen CY; Hsiao TH; Salunke SB; Chen JJ; Su KY; Yang SC; Hong TM; Chen CS; Yang PC
Am J Respir Crit Care Med; 2016 Apr; 193(7):753-66. PubMed ID: 26583948
[TBL] [Abstract][Full Text] [Related]
18. Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors.
Sun S; Zhang J; Wang N; Kong X; Fu F; Wang H; Yao J
Molecules; 2017 Dec; 23(1):. PubMed ID: 29295519
[TBL] [Abstract][Full Text] [Related]
19. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.
Tsou HR; Mamuya N; Johnson BD; Reich MF; Gruber BC; Ye F; Nilakantan R; Shen R; Discafani C; DeBlanc R; Davis R; Koehn FE; Greenberger LM; Wang YF; Wissner A
J Med Chem; 2001 Aug; 44(17):2719-34. PubMed ID: 11495584
[TBL] [Abstract][Full Text] [Related]
20. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase.
Lee JY; Park YK; Seo SH; So IS; Chung HK; Yang BS; Lee SJ; Park H; Lee YS
Arch Pharm (Weinheim); 2001 Nov; 334(11):357-60. PubMed ID: 11822173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
